Key Highlights

  • But a narrower H1 FY26 loss shows the turnaround is far from finished.
  • The stock has been volatile and heavily sold over the past 12 months, and the group is midway through a multi-year margin-recovery plan.
  • Healius sold Lumus Imaging to a consortium led by Affinity Equity Partners in a deal with an enterprise value of roughly $965 million, completing on 1 May 2025.
  • The transaction booked a profit on sale of about $375.2 million and, crucially, allowed Healius to repay its debt in full.

Debt gone, a special dividend paid and the balance sheet reset — Healius (ASX: HLS) has simplified into a pathology pure-play. But a narrower H1 FY26 loss shows the turnaround is far from finished.

Company Overview

Debt gone, a special dividend paid and the balance sheet reset — Healius (ASX: HLS) has simplified into a pathology pure-play. But a narrower H1 FY26 loss shows the turnaround is far from finished.

Recent Developments

Few ASX healthcare names have changed shape as dramatically as Healius Limited (ASX: HLS). Once a sprawling diagnostics group carrying more than a billion dollars of debt, the company has spent the past year selling assets, wiping its borrowings and handing cash back to shareholders. That reset has put Healius (ASX: HLS) firmly back in front of investors weighing whether the worst is behind Australia's second-largest pathology operator — or whether a cheap-looking share price simply reflects a business still fighting to make money.

Financial and Operational Snapshot

Healius (ASX: HLS) — Stock overview (Simply Wall St)

What May Be Watched Next

Several levers could support a re-rating if management delivers. These are forward-looking and not guaranteed: Healius is targeting high single-digit EBIT margins by June 2027, supported by laboratory automation, network consolidation and further support-cost reductions (with additional annualised savings targeted in FY26). For FY26, the company has guided — in forward-looking terms — to revenue growth broadly consistent with the second half of FY25 and a broadly flat labour cost base, with profit weighted to the second half. A debt-free balance sheet also gives the…

Key Risks

The bear case is straightforward. Healius remains loss-making on a statutory basis, and its margin-recovery target is still roughly two years out, leaving ample room for slippage. Wage inflation and Medicare funding settings are largely outside management's control. Execution risk on cost programs is high, competition in pathology is intense, and the shares have been deeply out of favour, trading well below prior levels. A stretched or delayed turnaround would test patience.

What does Healius (ASX do?

Debt gone, a special dividend paid and the balance sheet reset — Healius (ASX: HLS) has simplified into a pathology pure-play. But a narrower H1 FY26 loss shows the turnaround is far from finished.

What is the latest development?

Few ASX healthcare names have changed shape as dramatically as Healius Limited (ASX: HLS). Once a sprawling diagnostics group carrying more than a billion dollars of debt, the company has spent the past year selling…

What financial or operational point stands out?

Healius (ASX: HLS) — Stock overview (Simply Wall St)

What may be watched next?

Several levers could support a re-rating if management delivers. These are forward-looking and not guaranteed: Healius is targeting high single-digit EBIT margins by June 2027, supported by laboratory automation, network consolidation and further support-cost reductions…